La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Syros Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Syros Pharmaceuticals' Il CEO è Conley Chee, nominato in Dec2023, e ha un mandato di meno di un anno. la retribuzione annua totale è $ 1.04M, composta da 46% di stipendio e 54% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.084% delle azioni della società, per un valore di $ 34.21K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 11.3 anni.

Informazioni chiave

Conley Chee

Amministratore delegato

US$1.0m

Compenso totale

Percentuale dello stipendio del CEO	46.0%
Mandato del CEO	less than a year
Proprietà del CEO	0.5%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	11.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Jul 02

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Conley Chee rispetto agli utili di Syros Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

Compensazione vs Mercato: La retribuzione totale di Conley ($USD 1.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Conley con le performance aziendali.

AMMINISTRATORE DELEGATO

Conley Chee (54 yo)

less than a year

Mandato

US$1,041,697

Compensazione

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.46% $ 245.0k
Richard Young	Scientific Founder	no data	US$82.15k	0.040% $ 21.3k
Jason Haas	Chief Financial Officer	2.9yrs	US$833.02k	0.46% $ 249.1k
David Roth	Chief Medical Officer	8.8yrs	US$876.53k	0% $ 0
James Bradner	Founder	no data	Nessun dato	Nessun dato
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Karen Hunady	Director of Corporate Communications & Investor Relations	no data	Nessun dato	Nessun dato
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	1.9yrs	US$1.46m	0.15% $ 79.5k
Lisa Roberts	Vice President of Human Resources	1.7yrs	Nessun dato	Nessun dato
Kristin Stephens	Chief Development Officer	4.3yrs	Nessun dato	0.094% $ 50.5k

2.4yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di SYRS è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.46% $ 245.0k
Richard Young	Scientific Founder	12.8yrs	US$82.15k	0.040% $ 21.3k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.4yrs	Nessun dato	Nessun dato
Peter Karl Wirth	Independent Chairman	7.7yrs	US$110.40k	0.060% $ 32.0k
Mark Murcko	Member of Scientific Advisory Board	11.4yrs	Nessun dato	Nessun dato
Andrew Oh	Independent Director	2yrs	US$78.53k	0.060% $ 32.0k
Nancy Simonian	Director	11.4yrs	US$1.49m	0.51% $ 271.3k
Gerard Evan	Member of Scientific Advisory Board	11.4yrs	Nessun dato	Nessun dato
Scott Biller	Member of Scientific Advisory Board	11.4yrs	Nessun dato	Nessun dato
Bradley Bernstein	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Stefan Knapp	Member of Scientific Advisory Board	11.4yrs	Nessun dato	Nessun dato
Aviv Regev	Member of Scientific Advisory Board	11.4yrs	Nessun dato	Nessun dato

11.4yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di SYRS è composto da personale esperto e esperto (durata media dell'incarico 11.3 anni).

Syros Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Financial Officer recently bought US$161k worth of stock

Scientific Founder notifies of intention to sell stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Director exercised options and sold US$72k worth of stock

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Recent updates

Chief Financial Officer recently bought US$161k worth of stock

Price target decreased by 56% to US$8.75

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

New major risk - Financial position

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Scientific Founder notifies of intention to sell stock

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Director exercised options and sold US$72k worth of stock

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

New major risk - Share price stability

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Price target decreased by 16% to US$21.25

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Price target decreased by 16% to US$21.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 10% to US$26.50

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Price target decreased to US$25.40

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Consensus revenue estimates fall by 11%

Insufficient new directors

Consensus forecasts updated

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Consensus forecasts updated

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Consensus forecasts updated

Consensus estimates of losses per share improve by 11%

Price target decreased to US$14.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones